121 related articles for article (PubMed ID: 2105279)
1. The effect of the E2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, on the growth of a human gastric cell line, MKN45G.
Watson SA; Durrant LG; Morris DL
Int J Cancer; 1990 Jan; 45(1):90-4. PubMed ID: 2105279
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally AV
Int J Cancer; 1994 May; 57(4):574-80. PubMed ID: 7910153
[TBL] [Abstract][Full Text] [Related]
3. Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer.
Thomas FJ; Koss MA; Hogan DL; Isenberg JI
Am J Med; 1986 Aug; 81(2A):44-9. PubMed ID: 3092654
[TBL] [Abstract][Full Text] [Related]
4. Gastrin: growth enhancing effects on human gastric and colonic tumour cells.
Watson S; Durrant L; Morris D
Br J Cancer; 1989 Apr; 59(4):554-8. PubMed ID: 2713241
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of the gastric acid and serum gastrin-lowering effects of the prostaglandin E2 analog enprostil.
Baak LC; Jansen JB; Meijer JL; Lamers CB
Clin Pharmacol Ther; 1993 Jun; 53(6):668-4. PubMed ID: 8513659
[TBL] [Abstract][Full Text] [Related]
6. Effect of two-week treatment with enprostil (35 micrograms twice a day) on 24-hour serum gastrin levels.
Florent C; Cogoni C; Joubert M; Desaint B
Dig Dis Sci; 1990 Nov; 35(11):1352-7. PubMed ID: 2121423
[TBL] [Abstract][Full Text] [Related]
7. Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease.
Mahachai V; Walker K; Sevelius H; Thomson AB
Gastroenterology; 1985 Sep; 89(3):555-61. PubMed ID: 3926591
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between an H2-receptor antagonist and enprostil on 24-hour intragastric pH, serum gastrin concentration, and tissue immunoperoxidase staining for gastrin, somatostatin, and serotonin in a patient with metastatic gastrinoma.
Sherbaniuk R; Jewell LD; Yacoub W; Pinchbeck B; Salkie ML; Walker K; Mahachai V; Kirdeikis P; Zuk L; Brunet MK
Clin Ther; 1986; 8(6):667-88. PubMed ID: 2878726
[TBL] [Abstract][Full Text] [Related]
9. Intracellular gastrin in human gastrointestinal tumor cells.
Watson SA; Durrant LG; Wencyk PM; Watson AL; Morris DL
J Natl Cancer Inst; 1991 Jun; 83(12):866-71. PubMed ID: 2061947
[TBL] [Abstract][Full Text] [Related]
10. Enprostil reduces the increase of gastric corpus mucosal mass induced by the hydrogen-potassium-stimulated adenosine triphosphatase inhibitor BY 831-78 in the rat.
Inauen W; Rohner C; Koelz HR; Herdmann J; Schürer-Maly CC; Varga L; Halter F
Gastroenterology; 1989 Oct; 97(4):846-52. PubMed ID: 2570729
[TBL] [Abstract][Full Text] [Related]
11. Effect of a single oral dose of enprostil on gastric secretion and gastrin release. Studies in healthy volunteers and patients with pernicious anemia.
Buchanan N; Laferla G; Hearns J; Buchanan KD; Crean GP; McColl KE
Am J Med; 1986 Aug; 81(2A):40-3. PubMed ID: 3092653
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide.
Watson SA; Morris DL; Durrant LG; Robertson JF; Hardcastle JD
Eur J Cancer; 1992; 28A(8-9):1462-7. PubMed ID: 1355350
[TBL] [Abstract][Full Text] [Related]
13. Effect of enprostil on serum gastrin and pepsinogen A and C levels in patients on long-term treatment with omeprazole.
Meijer JL; Jansen JB; Biemond I; Kuijpers IJ; Lamers CB
Aliment Pharmacol Ther; 1994 Apr; 8(2):221-7. PubMed ID: 8038355
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory action of enprostil (4,5-dehydro-16-phenoxy-17,18,19,20-tetranor-PGE2) on tetra-gastrin stimulated acid secretion in human subjects.
Moriga M; Aono M; Narusawa H; Kohli Y; Kato T; Kajiyama G; Inoue M; Miyoshi A
Gastroenterol Jpn; 1989 Apr; 24(2):115-9. PubMed ID: 2501133
[TBL] [Abstract][Full Text] [Related]
15. Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.
Goa KL; Monk JP
Drugs; 1987 Nov; 34(5):539-59. PubMed ID: 3121276
[TBL] [Abstract][Full Text] [Related]
16. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer.
Dy DY; Whitehead RH; Morris DL
Cancer Res; 1992 Feb; 52(4):917-23. PubMed ID: 1737355
[TBL] [Abstract][Full Text] [Related]
17. Enprostil reduces G-cell hyperplasia and hypergastrinemia in duodenal ulcer.
Jewell LD; Yacoub W; Salkie ML; Sherbaniuk R; Walker K; Mahachai V; Kirdeikis P; Simpson I; Zuk L; Brunet MK
Clin Ther; 1987; 9(3):281-95. PubMed ID: 3111703
[TBL] [Abstract][Full Text] [Related]
18. Effects of prostaglandins on gastrin release from canine antral mucosal cells in primary culture.
Schepp W; Chan CB; Giraud AS; Avedian D; Chen MC; Chew P; Walsh JH; Soll AH
Am J Physiol; 1994 Feb; 266(2 Pt 1):G194-200. PubMed ID: 8141291
[TBL] [Abstract][Full Text] [Related]
19. Effect of synthetic prostaglandin E2 analog enprostil on omeprazole-induced hypergastrinemia and hyperpepsinogenemia.
Meijer JL; Crobach LF; Jansen JB; Lamers CB
Dig Dis Sci; 1994 Mar; 39(3):609-16. PubMed ID: 8131700
[TBL] [Abstract][Full Text] [Related]
20. Suppression of postprandial glucose, insulin, C-peptide, and glucose-dependent insulinotropic peptide (GIP) in man by oral administration of a prostaglandin analogue (enprostil).
Schwartz KE; Zaro B; Reynolds J; Duffy J; Saito T; Hunt JS; Sevelius H
Horm Metab Res; 1988 Oct; 20(10):637-40. PubMed ID: 3146539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
